LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

17.74 -1.06

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.69

Max

17.96

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

14.031

79.874

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+34.76% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

170M

956M

Vorige openingsprijs

18.8

Vorige sluitingsprijs

17.74

Nieuwssentiment

By Acuity

50%

50%

168 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 nov 2025, 16:49 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov 2025, 15:32 UTC

Acquisities, Fusies, Overnames

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov 2025, 23:50 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov 2025, 23:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 nov 2025, 16:05 UTC

Marktinformatie

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov 2025, 16:04 UTC

Marktinformatie

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov 2025, 15:54 UTC

Acquisities, Fusies, Overnames

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov 2025, 15:43 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov 2025, 15:41 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov 2025, 15:11 UTC

Marktinformatie

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov 2025, 14:26 UTC

Marktinformatie

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov 2025, 14:11 UTC

Marktinformatie

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov 2025, 14:11 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

27 nov 2025, 13:35 UTC

Marktinformatie

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov 2025, 13:33 UTC

Marktinformatie

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov 2025, 13:22 UTC

Marktinformatie

Global Equities Roundup: Market Talk

27 nov 2025, 13:22 UTC

Marktinformatie

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov 2025, 13:17 UTC

Marktinformatie

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov 2025, 11:13 UTC

Marktinformatie

European Gas Prices Come Under Pressure -- Market Talk

27 nov 2025, 11:07 UTC

Winsten

Genting: Positive About Prospects Over Longer Term

27 nov 2025, 11:06 UTC

Winsten

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov 2025, 11:04 UTC

Winsten

Genting: International Travel Demand Expected to Remain Resilient

27 nov 2025, 11:04 UTC

Winsten

Genting: Global Growth Expected to Remain Subdued

27 nov 2025, 11:04 UTC

Winsten

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov 2025, 10:59 UTC

Winsten

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov 2025, 10:58 UTC

Winsten

Genting Bhd 3Q Rev Rose 14% on Year

27 nov 2025, 10:56 UTC

Winsten

Genting Bhd 3Q Net MYR30.3M

27 nov 2025, 10:56 UTC

Winsten

Genting Bhd 3Q EPS MYR0.0079

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

34.76% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 24 USD  34.76%

Hoogste 26 USD

Laagste 22 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

168 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat